Chemistry:Elezanumab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AE12-1Y-QL; ABT-555 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Elezanumab (development names AE12-1Y-QL and ABT-555) is a fully human monoclonal antibody developed by AbbVie against repulsive guidance molecule A (RGMa). It has been tested in people with multiple sclerosis and acute ischemic stroke.[1][2][3][4]
References
- ↑ Huang, Lili; Fung, Emma; Bose, Sahana; Popp, Andreas; Böser, Preethne; Memmott, John; Kutskova, Yuliya A.; Miller, Renee et al. (November 2021). "Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models". Neurobiology of Disease 159: 105492. doi:10.1016/j.nbd.2021.105492. PMID 34478849.
- ↑ Kalluri, Hari V.; Rosebraugh, Matthew R.; Misko, Thomas P.; Ziemann, Adam; Liu, Wei; Cree, Bruce A. C. (February 2023). "Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants". Annals of Neurology 93 (2): 285–296. doi:10.1002/ana.26503. ISSN 0364-5134. PMID 36093738.
- ↑ Jacobson, Peer B.; Goody, Robin; Lawrence, Matthew; Mueller, Bernhard K.; Zhang, Xiaomeng; Hooker, Bradley A.; Pfleeger, Kimberly; Ziemann, Adam et al. (July 2021). "Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates". Neurobiology of Disease 155: 105385. doi:10.1016/j.nbd.2021.105385. PMID 33991647.
- ↑ Smith, Elaine; Ford, Andria L; Perez-Sanchez, Soledad; Shuaib, Ashfaq; Schwefel, Brittany; Ziemann, Adam (February 2022). "Abstract TP7: Phase 2a Study Of Elezanumab In Patients With Acute Ischemic Stroke" (in en). Stroke 53 (Suppl_1). doi:10.1161/str.53.suppl_1.TP7. ISSN 0039-2499. https://www.ahajournals.org/doi/10.1161/str.53.suppl_1.TP7.
 |  |
